摘要
目的观察比较特比奥(重组人血小板生成素,rh TPO)与巨和粒(重组人白细胞介素11,rh IL-11)治疗恶性实体瘤患者化疗后血小板减少的临床疗效和毒副反应。方法将化疗后出现血小板减少症的76例恶性实体瘤患者随机分成两组,其中一组38例患者在化疗后采用特比奥皮下注射治疗。另外一组38例患者在化疗后采用巨和粒皮下注射治疗,动态监测注射特比奥或巨和粒后患者血小板增长情况,c2检测比较二者临床疗效和不良反应。结果患者注射特比澳与巨和粒后血小板计数均显著升高,血小板计数恢复至100×109/L以上所需时间明显缩短,其中特比澳组血小板计数普遍高于巨和粒组,两组比较差异具有统计学意义(P<0.05),总缓解率特比澳组高于巨和粒组,差异具有统计学意义(P<0.05)。8例患者在巨和粒治疗后需要输注血小板,而特比澳组只4例需要输注血小板,差异有统计学意义。二组均出现一定程度的毒副反应,其中特比奥组(13.2%)低于巨和粒组(18.4%),差异无统计学意义,两组毒副反应均比较轻微,患者可以耐受。结论特比澳与巨和粒治疗恶性实体瘤患者化疗后血小板减少症安全有效,可以减轻化疗引起的血小板降低程度和持续时间,减少血小板的输注。
Objective To observe the clinical effects and toxicity of the rhTPO and rhIL-11in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant solid tumor.Methods76patients with malignant solid tumor who have the thrombocytopenia were randomized into two groups,38patients received the treatment of rhTPO,another group received the treatment of rhIL-11.Results Granulocyte-platelet counts were significantly increased after treatment,and the required time of the platelet count recovered to100×109/L was significantly shorter,the difference was significant(P<0.05).8patients after treatment with rhIL-11need transfusion of platelet,while the rhTPO group need only4cases of platelet transfusion.Two groups all have lower toxicity,the rhTPO group(13.2%)is less than rhIL-11group(18.4%),no significant difference between these two groups,the toxicity were mild,patients can be tolerated.Conclusion The rhTPO and rhIL-11can reduce chemotherapy-induced thrombocytopenia extent and duration and reduce the platelet transfusion,the treatment is effective and safety to patients with malignant solid tumor.
作者
魏阳
周行
周进
谢华
王理阳
赵新
姚文秀
Wei Yang;Zhou Hang;Zhou Jin;Xie Hua;Wang Li-yang;Zhao Xin;Yao Wen-xiu(Departmeng of Medical Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan, 610041, China)
出处
《当代医学》
2017年第30期60-63,共4页
Contemporary Medicine
